Mark B. Leick

Broad Institute — United States

Medicine · Health Sciences

21h-index3.4kcitations161works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(121), Immune Cell Function and Interaction(22), Monoclonal and Polyclonal Antibodies Research(14), Virus-based gene therapy research(13), Nanowire Synthesis and Applications(13)

Publications161 total

Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Nature Communications·2025Open Access
A pooled primate screen finds that MYD88-CD40 boosts CAR-T
Blood·2025Open Access
Isolated oral CAR+ T cell lymphoma after tisagenlecleucel
Molecular Therapy·2025· 1 citedOpen Access
Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
Clinical Cancer Research·2025Open Access
Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia
Blood·2025
Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma
Blood·2025
First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance
Blood·2025Open Access
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Regular and Young Investigator Award Abstracts·2025Open Access
262 Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Regular and Young Investigator Award Abstracts·2025Open Access
280 Cell atlas-resolved discovery and targeting of novel CAR antigens in anaplastic thyroid carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
EXTH-47. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Neuro-Oncology·2025Open Access
On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models
Nature Communications·2025· 1 citedOpen Access
Genomic correlates of clinical CAR-T cell activity
2025Open Access
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>
Transplantation and Cellular Therapy·2025Open Access
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma
Nature·2025· 6 citedOpen Access
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Supplementary Figure 7 from Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
2025Open Access
Supplementary Figure 13 from Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
2025Open Access
Supplementary Figure 3 from Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
2025Open Access
Supplementary Figure 12 from Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
2025Open Access
page 1 of 9Next →

Frequent Co-authors

Marcela V. Maus(45), Matthew J. Frigault(23), Amanda A. Bouffard(21), Rebecca C. Larson(20), Michael C. Kann(19), Kathleen Gallagher(18), Bryan D. Choi(14), Trisha R. Berger(14), Stefanie R. Bailey(13), Irene Scarfò(12), Andrea Schmidts(10), Marc Wehrli(10), Max Jan(9), Harrison Silva(9), Diego Salas‐Benito(9), Katelin Katsis(8), Filippo Birocchi(8), Tamina Kienka(8), Felix Korell(8), Nicholas J. Haradhvala(7)